Crescent Biopharma, Inc. Common Stock
CBIO
About: Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2,588% more capital invested
Capital invested by funds: $6.46M [Q1] → $174M (+$167M) [Q2]
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
16.19% more ownership
Funds ownership: 0.48% [Q1] → 16.66% (+16.19%) [Q2]
12% less funds holding
Funds holding: 34 [Q1] → 30 (-4) [Q2]
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
HC Wainwright & Co.
Mitchell S. Kapoor
|
$25
|
Buy
Reiterated
|
27 Aug 2025 |
|
Jefferies
Akash Tewari
|
$26
|
Buy
Initiated
|
25 Aug 2025 |
|
Wedbush
Robert Driscoll
|
$27
|
Outperform
Initiated
|
14 Jul 2025 |
|
Stifel
Stephen Willey
|
$28
|
Buy
Initiated
|
25 Jun 2025 |
|
LifeSci Capital
Charles Zhu
|
$22
|
Outperform
Initiated
|
18 Jun 2025 |
Financial journalist opinion
